Cybin, a clinical-stage neuropsychiatry company, announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the Cantor Global Healthcare Conference scheduled for September 3-5, 2025. The session will be webcast live on Friday, September 5, at 10:20 a.m. ET, with an archived replay available on Cybin's investor relations website. To view the full press release, visit https://ibn.fm/N8ObB.
The company is developing next-generation treatment options for mental healthcare, focusing on addressing the large unmet need for people suffering from mental health conditions. Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN.
Cybin is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. This treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, the company is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The company also maintains a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, and Ireland. The company's participation in the Cantor Global Healthcare Conference represents an important opportunity to showcase its clinical progress and research developments to the investment community and healthcare professionals. This presentation could potentially influence investor confidence and industry perception of psychedelic-based treatments.
The conference appearance comes at a critical time for the psychedelic medicine industry, as companies like Cybin work to demonstrate the clinical efficacy and commercial viability of their novel treatments. Successful development of these therapies could significantly impact mental healthcare by providing new treatment options for conditions that have traditionally been difficult to treat with conventional pharmaceuticals.
